{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:18:13Z","timestamp":1792153093550,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA-77188"],"award-info":[{"award-number":["CA-77188"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["1068\/2005"],"award-info":[{"award-number":["1068\/2005"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000869","name":"Susan G. Komen for the Cure","doi-asserted-by":"publisher","award":["BCTR01-00537"],"award-info":[{"award-number":["BCTR01-00537"]}],"id":[{"id":"10.13039\/100000869","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gruppo Bancario Credito Valtellinese","award":["Research Fellowship"],"award-info":[{"award-number":["Research Fellowship"]}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF 2004\/86"],"award-info":[{"award-number":["RF 2004\/86"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lega Italiana per la Lotta contro i Tumori"},{"DOI":"10.13039\/501100007076","name":"Fondazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005029","name":"Helse Vest Regionalt Helsef\u00f8retak","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005029","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s10549-016-3932-7","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T14:45:07Z","timestamp":1470149107000},"page":"97-108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen"],"prefix":"10.1007","volume":"159","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4131-2030","authenticated-orcid":false,"given":"Harriet","family":"Johansson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Gjerde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Lattanzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Macis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliana","family":"Guerrieri-Gonzaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Aristarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Mellgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst","family":"Lien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"DeCensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,2]]},"reference":[{"key":"3932_CR1","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"C Davies","year":"2011","unstructured":"Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771\u2013784","journal-title":"Lancet"},{"key":"3932_CR2","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/S0140-6736(13)60140-3","volume":"381","author":"J Cuzick","year":"2013","unstructured":"Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, Decensi A et al (2013) Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 381:1827\u20131834","journal-title":"Lancet"},{"key":"3932_CR3","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1093\/jnci\/87.9.645","volume":"87","author":"LE Rutqvist","year":"1995","unstructured":"Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 87:645\u2013651","journal-title":"J Natl Cancer Inst"},{"key":"3932_CR4","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","volume":"351","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1998","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451\u20131467","journal-title":"Lancet"},{"key":"3932_CR5","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/jnci\/95.11.779","volume":"95","author":"A Decensi","year":"2003","unstructured":"Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER et al (2003) A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 95:779\u2013790","journal-title":"J Natl Cancer Inst"},{"key":"3932_CR6","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.1200\/JCO.2006.09.4318","volume":"25","author":"A Decensi","year":"2007","unstructured":"Decensi A, Gandini S, Serrano D, Cazzaniga M, Pizzamiglio M, Maffini F et al (2007) Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users. J Clin Oncol 25:4201\u20134209","journal-title":"J Clin Oncol"},{"key":"3932_CR7","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/FPC.0b013e3283656bc1","volume":"23","author":"DJ Klein","year":"2013","unstructured":"Klein DJ, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE (2013) PharmGKB summary: tamoxifen pathway, pharmacokinetics. Pharmacogenet Genomics 23:643\u2013647","journal-title":"Pharmacogenet Genomics"},{"key":"3932_CR8","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1200\/JCO.2009.25.7246","volume":"28","author":"K Kiyotani","year":"2010","unstructured":"Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M et al (2010) Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 28:1287\u20131293","journal-title":"J Clin Oncol"},{"key":"3932_CR9","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/clpt.2011.32","volume":"89","author":"L Madlensky","year":"2011","unstructured":"Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW et al (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 89:718\u2013725","journal-title":"Clin Pharmacol Ther"},{"key":"3932_CR10","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2217\/pgs.13.47","volume":"14","author":"S Margolin","year":"2013","unstructured":"Margolin S, Lindh JD, Thoren L, Xie H, Koukel L, Dahl ML et al (2013) CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients. Pharmacogenomics 14:613\u2013622","journal-title":"Pharmacogenomics"},{"key":"3932_CR11","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1001\/jama.2009.1420","volume":"302","author":"W Schroth","year":"2009","unstructured":"Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S et al (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302:1429\u20131436","journal-title":"JAMA"},{"key":"3932_CR12","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.1158\/1078-0432.CCR-07-5235","volume":"14","author":"WG Newman","year":"2008","unstructured":"Newman WG, Hadfield KD, Latif A, Roberts SA, Shenton A, McHague C et al (2008) Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res 14:5913\u20135918","journal-title":"Clin Cancer Res"},{"key":"3932_CR13","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/annonc\/mdn155","volume":"19","author":"Y Xu","year":"2008","unstructured":"Xu Y, Sun Y, Yao L, Shi L, Wu Y, Ouyang T et al (2008) Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 19:1423\u20131429","journal-title":"Ann Oncol"},{"key":"3932_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10549-008-0272-2","volume":"118","author":"MJ Bijl","year":"2009","unstructured":"Bijl MJ, van Schaik RH, Lammers LA, Hofman A, Vulto AG, van GT et al (2009) The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat 118:125\u2013130","journal-title":"Breast Cancer Res Treat"},{"key":"3932_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10549-009-0328-y","volume":"119","author":"T Cajal","year":"2010","unstructured":"Cajal T, Altes A, Pare L, del RE, Alonso C, Barnadas A et al (2010) Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat 119:33\u201338","journal-title":"Breast Cancer Res Treat"},{"key":"3932_CR16","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3346\/jkms.2011.26.8.1007","volume":"26","author":"HS Park","year":"2011","unstructured":"Park HS, Choi JY, Lee MJ, Park S, Yeo CW, Lee SS et al (2011) Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment. J Korean Med Sci 26:1007\u20131013","journal-title":"J Korean Med Sci"},{"key":"3932_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1208\/s12248-011-9313-6","volume":"14","author":"LK Teh","year":"2012","unstructured":"Teh LK, Mohamed NI, Salleh MZ, Rohaizak M, Shahrun NS, Saladina JJ et al (2012) The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1. AAPS J 14:52\u201359","journal-title":"AAPS J"},{"key":"3932_CR18","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.7314\/APJCP.2012.13.9.4549","volume":"13","author":"C Sukasem","year":"2012","unstructured":"Sukasem C, Sirachainan E, Chamnanphon M, Pechatanan K, Sirisinha T, Ativitavas T et al (2012) Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand. Asian Pac J Cancer Prev 13:4549\u20134553","journal-title":"Asian Pac J Cancer Prev"},{"key":"3932_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00280-012-1891-1","volume":"70","author":"SE Damodaran","year":"2012","unstructured":"Damodaran SE, Pradhan SC, Umamaheswaran G, Kadambari D, Reddy KS, Adithan C (2012) Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy. Cancer Chemother Pharmacol 70:75\u201381","journal-title":"Cancer Chemother Pharmacol"},{"key":"3932_CR20","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1158\/1078-0432.CCR-12-2153","volume":"19","author":"MP Goetz","year":"2013","unstructured":"Goetz MP, Suman VJ, Hoskin TL, Gnant M, Filipits M, Safgren SL et al (2013) CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res 19:500\u2013507","journal-title":"Clin Cancer Res"},{"key":"3932_CR21","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1200\/JCO.2006.06.8072","volume":"24","author":"B Bonanni","year":"2006","unstructured":"Bonanni B, Macis D, Maisonneuve P, Johansson H, Gucciardo G, Oliviero P et al (2006) Polymorphism in the CYP2D6 Tamoxifen-Metabolizing Gene Influences Clinical Effect but Not Hot Flashes: data From the Italian Tamoxifen Trial. J Clin Oncol 24:3708\u20133709","journal-title":"J Clin Oncol"},{"key":"3932_CR22","doi-asserted-by":"publisher","first-page":"6944","DOI":"10.1158\/1078-0432.CCR-11-0860","volume":"17","author":"MP Goetz","year":"2011","unstructured":"Goetz MP, Schaid DJ, Wickerham DL, Safgren S, Mushiroda T, Kubo M et al (2011) Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: results from the NSABP P1 and P2 Clinical Trials. Clin Cancer Res 17:6944\u20136951","journal-title":"Clin Cancer Res"},{"key":"3932_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/jnci\/djs126","volume":"104","author":"JM Rae","year":"2012","unstructured":"Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP et al (2012) CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients. J Natl Cancer Inst 104:452\u2013460","journal-title":"J Natl Cancer Inst"},{"key":"3932_CR24","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/jnci\/djs125","volume":"104","author":"MM Regan","year":"2012","unstructured":"Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R et al (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 104:441\u2013451","journal-title":"J Natl Cancer Inst"},{"key":"3932_CR25","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/bjc.2012.278","volume":"107","author":"I Sestak","year":"2012","unstructured":"Sestak I, Kealy R, Nikoloff M, Fontecha M, Forbes JF, Howell A et al (2012) Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial. Br J Cancer 107:230\u2013233","journal-title":"Br J Cancer"},{"key":"3932_CR26","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/jhg.2013.39","volume":"58","author":"K Kiyotani","year":"2013","unstructured":"Kiyotani K, Mushiroda T, Zembutsu H, Nakamura Y (2013) Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies. J Hum Genet 58:327\u2013333","journal-title":"J Hum Genet"},{"key":"3932_CR27","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10549-013-2677-9","volume":"141","author":"EA Lien","year":"2013","unstructured":"Lien EA, Soiland H, Lundgren S, Aas T, Steen VM, Mellgren G et al (2013) Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment. Breast Cancer Res Treat 141:243\u2013248","journal-title":"Breast Cancer Res Treat"},{"key":"3932_CR28","doi-asserted-by":"publisher","first-page":"7053","DOI":"10.1158\/1078-0432.CCR-09-1354","volume":"15","author":"B Bonanni","year":"2009","unstructured":"Bonanni B, Serrano D, Gandini S, Guerrieri-Gonzaga A, Johansson H, Macis D et al (2009) Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia. Clin Cancer Res 15:7053\u20137060","journal-title":"Clin Cancer Res"},{"key":"3932_CR29","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1200\/JCO.2008.19.3797","volume":"27","author":"A Decensi","year":"2009","unstructured":"Decensi A, Robertson C, Guerrieri-Gonzaga A, Serrano D, Cazzaniga M, Mora S et al (2009) Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J Clin Oncol 27:3749\u20133756","journal-title":"J Clin Oncol"},{"key":"3932_CR30","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10549-013-2768-7","volume":"142","author":"H Johansson","year":"2013","unstructured":"Johansson H, Bonanni B, Gandini S, Guerrieri-Gonzaga A, Cazzaniga M, Serrano D et al (2013) Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide. Breast Cancer Res Treat 142:569\u2013578","journal-title":"Breast Cancer Res Treat"},{"key":"3932_CR31","doi-asserted-by":"publisher","first-page":"R47","DOI":"10.1186\/bcr3439","volume":"15","author":"D Serrano","year":"2013","unstructured":"Serrano D, Lazzeroni M, Gandini S, Macis D, Johansson H, Gjerde J et al (2013) A randomized phase II pre-surgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor positive breast cancer. Breast Cancer Res 15:R47","journal-title":"Breast Cancer Res"},{"key":"3932_CR32","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/tpj.2010.17","volume":"11","author":"D Serrano","year":"2011","unstructured":"Serrano D, Lazzeroni M, Zambon CF, Macis D, Maisonneuve P, Johansson H et al (2011) Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial. Pharmacogenomics J 11:100\u2013107","journal-title":"Pharmacogenomics J"},{"key":"3932_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.chroma.2005.01.004","volume":"1082","author":"J Gjerde","year":"2005","unstructured":"Gjerde J, Kisanga ER, Hauglid M, Holm PI, Mellgren G, Lien EA (2005) Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry. J Chromatogr A 1082:6\u201314","journal-title":"J Chromatogr A"},{"key":"3932_CR34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/annonc\/mdm434","volume":"19","author":"J Gjerde","year":"2008","unstructured":"Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, Kisanga ER et al (2008) Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 19:56\u201361","journal-title":"Ann Oncol"},{"key":"3932_CR35","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s10549-012-2000-1","volume":"133","author":"NGL Jager","year":"2012","unstructured":"Jager NGL, Rosing H, Linn SC, Schellens JHM, Beijnen JH (2012) Importance of highly selective LC-MS\/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen. Breast Cancer Res Treat 133:793\u2013798","journal-title":"Breast Cancer Res Treat"},{"key":"3932_CR36","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/clpt.2011.27","volume":"89","author":"TE Murdter","year":"2011","unstructured":"Murdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W et al (2011) Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89:708\u2013717","journal-title":"Clin Pharmacol Ther"},{"key":"3932_CR37","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1158\/1078-0432.CCR-03-0538","volume":"10","author":"ER Kisanga","year":"2004","unstructured":"Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, Pigatto F, Pesci-Feltri A, Robertson C et al (2004) Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res 10:2336\u20132343","journal-title":"Clin Cancer Res"},{"key":"3932_CR38","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/annonc\/mdp408","volume":"21","author":"A Guerrieri-Gonzaga","year":"2010","unstructured":"Guerrieri-Gonzaga A, Botteri E, Lazzeroni M, Rotmensz N, Goldhirsch A, Varricchio C et al (2010) Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study. Ann Oncol 21:949\u2013954","journal-title":"Ann Oncol"},{"key":"3932_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10549-004-0746-9","volume":"88","author":"H Johansson","year":"2004","unstructured":"Johansson H, Baglietto L, Guerrieri-Gonzaga A, Bonanni B, Mariette F, Macis D et al (2004) Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer. Breast Cancer Res Treat 88:63\u201373","journal-title":"Breast Cancer Res Treat"},{"key":"3932_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10549-007-9577-9","volume":"108","author":"H Johansson","year":"2008","unstructured":"Johansson H, Gandini S, Bonanni B, Mariette F, Guerrieri-Gonzaga A, Serrano D et al (2008) Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women. Breast Cancer Res Treat 108:57\u201367","journal-title":"Breast Cancer Res Treat"},{"key":"3932_CR41","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0140-6736(98)85011-3","volume":"352","author":"U Veronesi","year":"1998","unstructured":"Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C et al (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352:93\u201397","journal-title":"Lancet"},{"key":"3932_CR42","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/jnci\/djk154","volume":"99","author":"U Veronesi","year":"2007","unstructured":"Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G et al (2007) Tamoxifen for the Prevention of Breast Cancer: late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy. J Natl Cancer Inst 99:727\u2013737","journal-title":"J Natl Cancer Inst"},{"key":"3932_CR43","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1093\/annonc\/mdt244","volume":"24","author":"A Decensi","year":"2013","unstructured":"Decensi A, Bonanni B, Maisonneuve P, Serrano D, Omodei U, Varricchio C et al (2013) A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study. Ann Oncol 24:2753\u20132760","journal-title":"Ann Oncol"},{"key":"3932_CR44","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ctrv.2011.06.009","volume":"38","author":"J Iqbal","year":"2012","unstructured":"Iqbal J, Ginsburg OM, Wijeratne TD, Howell A, Evans G, Sestak I et al (2012) Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review. Cancer Treat Rev 38:318\u2013328","journal-title":"Cancer Treat Rev"},{"key":"3932_CR45","doi-asserted-by":"publisher","first-page":"A56","DOI":"10.1158\/1940-6207.PREV-11-A56","volume":"4","author":"S Zanardi","year":"2011","unstructured":"Zanardi S, Branchi D, Ponti A, Cruciani G, D\u2019Amico C, Cortesi L et al (2011) Abstract A56: randomized, placebo-controlled, phase III trial of low-dose tamoxifen in women with intraepithelial neoplasia. Cancer Prev Res 4:A56","journal-title":"Cancer Prev Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-016-3932-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-016-3932-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-016-3932-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-016-3932-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T12:50:06Z","timestamp":1589719806000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-016-3932-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["3932"],"URL":"https:\/\/doi.org\/10.1007\/s10549-016-3932-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"16 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}